Dr. Lager has more than 20 years of experience in oncology drug development including treatment of solid tumors and hematologic malignancies in all phases of development. She led strategy and operations for two mid-stage clinical programs and an emerging immuno-oncology pipeline as Chief Medical Officer at iTeos Therapeutics. As the Head of Development for Oncology at Sanofi Genzyme, Dr. Lager oversaw the development and registration of Libtayo (anti-PD1) and Sarclisa (anti-CD38). At GlaxoSmithKline, she contributed to the development and registration of Votrientin renal cell cancer and soft tissue sarcoma. Dr. Lager earned her medical degree from Duke University, her fellowship in Pediatric Hematology/Oncology at Duke University, and completed a joint fellowship in Oncology Drug Development between Duke University and GlaxoSmithKline.